Diabetes Prevention Through Antiviral Treatment in Biobreeding Rats
Bo Niklasson1, Gustav Arbrandt1, Anne Kawecki2
11 Department of Medical Cell Biology, Uppsala University , Uppsala, Sweden .
Abstract:
A picornavirus (Ljungan virus) has been associated with diabetes in its wild rodent reservoir and in diabetes-prone biobreeding (DP-BB) rats. We attempted to alter the development of diabetes in DP-BB rats using two anti-picornavirus compounds (pleconaril and APO-N039), singly or in combination. Antiviral therapy was initiated 2 weeks before expected onset of diabetes. Pleconaril or APO-N039 alone did not affect the debut of diabetes. However, animals receiving a combination of both compounds were protected for at least the entire period of treatment (4 weeks after expected time of diabetes onset). Immunohistochemistry demonstrated that the presence and distribution of virus antigen in the pancreatic islets coincided with the clinical status of the animal. Data indicate that a treatable picornavirus can be involved in the cellular assault resulting in diabetes and in these cases the disease mechanism appears to involve a virus present in the pancreatic beta cell mass itself.
Insights
A picornavirus infection linked to diabetes was treated in rats. Combining two antiviral drugs, pleconaril and APO-N039, prevented diabetes onset, suggesting a treatable viral cause for the disease.
Area of Science:
- Virology
- Endocrinology
- Immunology
Background:
- Picornaviruses, including Ljungan virus, are implicated in diabetes development in rodent models.
- Diabetes-prone biobreeding (DP-BB) rats serve as a model for studying virus-induced diabetes.
Purpose of the Study:
- To investigate the efficacy of antiviral compounds pleconaril and APO-N039 in preventing or altering diabetes development in DP-BB rats.
- To explore the role of picornavirus infection in the pathogenesis of diabetes in this model.
Main Methods:
- DP-BB rats received antiviral therapy with pleconaril and/or APO-N039 starting two weeks before expected diabetes onset.
- Diabetes incidence and progression were monitored throughout the treatment period.
- Immunohistochemistry was used to detect viral antigens in pancreatic islets.
Main Results:
- Neither pleconaril nor APO-N039 alone significantly affected diabetes onset.
- Combination therapy with both pleconaril and APO-N039 protected DP-BB rats from diabetes for at least four weeks post-treatment.
- Viral antigen presence in pancreatic islets correlated with the clinical diabetic status of the animals.
Conclusions:
- A treatable picornavirus infection may contribute to diabetes development.
- The disease mechanism appears to involve the virus directly within pancreatic beta cells.
- Combined antiviral therapy shows potential for managing virus-associated diabetes.
